The Effect of Bifidobacterium animalis subsp. lactis MN-Gup on Glucose Metabolism, Gut Microbiota, and Their Metabolites in Type 2 Diabetic Mice

Jun 19, 2024Nutrients

Bifidobacterium animalis MN-Gup’s impact on blood sugar, gut bacteria, and their products in mice with type 2 diabetes

AI simplified

Abstract

A high-dose of MN-Gup significantly reduced fasting blood glucose levels in mice.

  • MN-Gup was administered at doses of 2 × 10^9 CFU/kg and 1 × 10^9 CFU/kg over 6 weeks.
  • Significant increases in , especially acetate, were observed in the MN-Gup group.
  • GLP-1 levels were also significantly elevated in the MN-Gup treated mice.
  • The treatment led to a decrease in insulin resistance as measured by the homeostasis model assessment (HOMA-IR).
  • The gut microbiota composition was altered, with increases in beneficial bacteria and decreases in potentially harmful ones.
  • Correlation analysis indicated a positive relationship between certain gut bacteria and GLP-1 levels.

AI simplified

Key numbers

3.83 mmol/L
Decrease in Fasting Blood Glucose (FBG)
Difference in FBG levels between high-dose MN-Gup group and control group.
not provided
Increase in GLP-1 Levels
Comparison of GLP-1 levels in MN-Gup treated groups vs. control group.
not provided
Increase in Acetic Acid Levels
Comparison of acetic acid levels in MN-Gup treated groups vs. control group.

Full Text

What this is

  • This research investigates the effects of Bifidobacterium animalis subsp. lactis MN-Gup on glucose metabolism in type 2 diabetic mice.
  • The study evaluates how MN-Gup influences fasting blood glucose levels, insulin resistance, gut microbiota composition, and the secretion of () and GLP-1.
  • Findings indicate that MN-Gup has significant hypoglycemic effects and can modulate gut microbiota in a dose-dependent manner.

Essence

  • Bifidobacterium animalis subsp. lactis MN-Gup significantly reduces fasting blood glucose levels and insulin resistance in type 2 diabetic mice, while promoting beneficial gut microbiota and increasing and GLP-1 secretion.

Key takeaways

  • High-dose MN-Gup treatment significantly reduced fasting blood glucose (FBG) levels and homeostasis model assessment-insulin resistance (HOMA-IR) in type 2 diabetic mice compared to control groups.
  • The treatment increased levels of , particularly acetate, and (GLP-1), suggesting a mechanism for its hypoglycemic effects.
  • MN-Gup altered gut microbiota composition, increasing beneficial bacteria while decreasing potentially harmful strains, indicating a role in metabolic health.

Caveats

  • The study is limited to a mouse model, which may not fully replicate human diabetes physiology and treatment responses.
  • Further research is needed to explore the long-term effects and safety of MN-Gup in human subjects.

Definitions

  • Type 2 Diabetes Mellitus (T2DM): A metabolic disorder characterized by chronic hyperglycemia due to insulin resistance and impaired insulin secretion.
  • Short-Chain Fatty Acids (SCFAs): Fatty acids with fewer than six carbon atoms, produced by gut bacteria during the fermentation of dietary fibers, playing a role in gut health and metabolism.
  • Glucagon-Like Peptide-1 (GLP-1): An incretin hormone that enhances insulin secretion and lowers blood glucose levels, also involved in appetite regulation.

AI simplified

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free